On June 16, 2021, Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced the pricing of its initial public offering of 14,035,789 shares of its common stock at a price to the public of $19.00 per share. The gross proceeds to Verve from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $266.7 million. All of the shares are being offered by Verve. In addition, Verve has granted the underwriters a 30-day option to purchase up to an additional 2,105,368 shares of its common stock at the initial public offering price less the underwriting discounts and commissions. The shares began trading on the Nasdaq Global Select Market on June 17, 2021, under the ticker symbol “VERV.” The offering is expected to close on June 21, 2021, subject to the satisfaction of customary closing conditions.

Wilson Sonsini has represented Verve Therapeutics in patent matters since the company's formation. The team that advised Verve on IP matters related to the IPO includes Vern Norviel, Clark Lin, Ying Chen, Angel Wang, and Moonkyoung Um.

For more information, please see Verve’s press release.